Reaction
Musculoskeletal Deformity reporting signals
As of the last recalculation, Musculoskeletal Deformity appears in 233 FAERS reports alongside 26 co-occurring drug terms. The strongest observed disproportionality signal is SULFASALAZINE (PRR 385.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Sulfasalazine | 138 | 385.0 | 385.7 |
| Diclofenac Potassium, Film Coated | 28 | 337.7 | 338.8 |
| Diclofenac Potassium Tablets | 28 | 337.5 | 338.6 |
| Leflunomide | 136 | 277.5 | 277.8 |
| Diclofenac Potassium | 28 | 262.9 | 263.6 |
| Adalimumab-Fkjp | 86 | 262.3 | 262.8 |
| Adalimumab-Aaty | 86 | 256.7 | 257.2 |
| Tocilizumab | 135 | 249.9 | 250.2 |
| Hydroxychloroquine Sulfate | 120 | 241.5 | 241.9 |
| Calcium Gluconate | 28 | 235.8 | 236.3 |
| Adalimumab-Adaz | 86 | 230.2 | 230.5 |
| Cortisone Acetate | 28 | 230.1 | 230.7 |
| Abatacept | 136 | 209.3 | 209.5 |
| Desoximetasone | 25 | 131.2 | 131.4 |
| Infliximab | 129 | 117.0 | 117.1 |
| Pseudoephedrine Hydrochloride | 10 | 90.8 | 90.9 |
| Diclofenac Sodium 1% | 30 | 86.0 | 86.0 |
| Diclofenac Sodium Topical | 30 | 86.0 | 86.0 |
| Diclofenac Sodium Topical Gel, 1% | 30 | 85.8 | 85.9 |
| Pseudoephedrine Hcl | 10 | 84.7 | 84.7 |
| Cetirizine Hydrochloride Allergy | 20 | 64.4 | 64.5 |
| Cetirizine Hydrochloride Tablets | 20 | 64.4 | 64.5 |
| Zidovudine | 9 | 62.5 | 62.5 |
| Darunavir | 10 | 61.7 | 61.7 |
| Raltegravir | 10 | 56.5 | 56.5 |
| Golimumab | 31 | 37.1 | 37.1 |